AB-8939 is under clinical development by AB Science and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AB-8939’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AB-8939 overview

AB-8939 is under development for the treatment of acute myeloid leukemia(AML). The therapeutic candidate is a small molecule. It acts by targeting tubulin.

AB Science overview

AB Science (ABS) is a pharmaceutical company. It offers protein kinase inhibitors. The company’s lead compound Masitinib, is a orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, and Lyn in several human indications such as oncology, inflammatory diseases, and central nervous system diseases. AB Science has developed several medicines for humans, on-going phase 2 and phase 3 studies in oncology and non-oncology diseases. The company is commercializing its lead product candidate in human and veterinary medicine. It has operations in France and the US. ABS is headquartered in Paris, France.

For a complete picture of AB-8939’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.